• Iovance Biotherapeutics will present lifileucel clinical results at the ESMO Congress in Madrid on October 23-27, 2026.
• Final Phase 2 results showed deep, durable responses with lifileucel combined with pembrolizumab in previously untreated advanced melanoma.
• The findings support the ongoing Phase 3 TILVANCE-301 trial evaluating lifileucel earlier in advanced melanoma treatment.
• A pilot trial showed durable responses in previously treated undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, supporting the ongoing SARATOGA registrational trial.
• An indirect comparison suggested improved long-term overall survival with lifileucel versus standard treatments in anti-PD-1-resistant advanced melanoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190700PRIMZONEFULLFEED9847932) on October 19, 2026, and is solely responsible for the information contained therein.